Related Experiment Video
Updated: Mar 2, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A
Evelyn Balsells1, Laurence Guillot1, Harish Nair1
1Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Teviot Place, Edinburgh, United Kingdom.
Insights
Pneumococcal conjugate vaccines (PCV) reduced invasive pneumococcal disease (IPD). However, non-vaccine serotypes, particularly 19A, remain a concern post-PCV introduction, with significant regional variations. Continued surveillance is crucial.
Area of Science:
- Microbiology
- Vaccinology
- Epidemiology
Background:
- Routine immunization with pneumococcal conjugate vaccines (PCV7/10/13) has significantly reduced invasive pneumococcal disease (IPD) caused by vaccine serotypes.
- An observed increase in IPD due to non-vaccine serotypes, known as serotype replacement, necessitates understanding individual serotype contributions.
- Serotype distribution in children is critical for evaluating the overall impact of PCVs and guiding future vaccine development.
Purpose of the Study:
- To examine the distribution of pneumococcal serotypes in children following the introduction of PCVs.
- To identify the leading serotypes associated with childhood IPD in the post-PCV era.
- To assess the impact of serotype replacement and regional variations in IPD epidemiology.
Main Methods:
- Systematic literature search for studies and surveillance reports on childhood IPD serotypes (2000-2015).
- Data differentiation based on vaccine type administered: PCV7 or higher valent PCVs (PCV10/PCV13).
- Meta-analysis to estimate the proportional contributions of frequent serotypes in childhood IPD.
Main Results:
- Serotype 19A was the predominant cause of IPD (21.8%) in the PCV7 era, with a lower contribution (14.2%) in the PCV10/PCV13 era.
- Non-PCV13 serotypes accounted for 42.2% of childhood IPD cases, with significant regional variations (e.g., 71.9% in Europe, 9.2% in Eastern Mediterranean).
- Key non-PCV13 serotypes included 22F, 12F, 33F, 24F, 15C, 15B, 23B, 10A, and 38, with regional rank order differences.
Conclusions:
- Childhood IPD involves a diverse range of serotypes beyond those included in current vaccines.
- Non-PCV13 serotypes represent a substantial proportion of IPD cases, particularly in the early years after higher valent PCV introduction.
- Geographic diversity in serotype distribution underscores the need for ongoing surveillance to inform vaccine design and public health recommendations, especially in resource-limited settings.
Background:
Routine immunisation with pneumococcal conjugate vaccines (PCV7/10/13) has reduced invasive pneumococcal disease (IPD) due to vaccine serotypes significantly. However, an increase in disease due to non-vaccine types, or serotype replacement, has been observed. Serotypes' individual contributions to IPD play a critical role in determining the overall effects of PCVs. This study examines the distribution of pneumococcal serotypes in children to identify leading serotypes associated with IPD post-PCV introduction.
Methods:
A systematic search was performed to identify studies and surveillance reports (published between 2000 and December 2015) of pneumococcal serotypes causing childhood IPD post-PCV introduction. Serotype data were differentiated based on the PCV administered during the study period: PCV7 or higher valent PCVs (PCV10 or PCV13). Meta-analysis was conducted to estimate the proportional contributions of the most frequent serotypes in childhood IPD in each period.
Results:
We identified 68 studies reporting serotype data among IPD cases in children. We analysed data from 38 studies (14 countries) where PCV7 was administered and 20 (24 countries) where PCV10 or PCV13 have been introduced. Studies reported early and late periods of PCV7 administration (range: 2001∓13). In these settings, serotype 19A was the most predominant cause of childhood IPD, accounting for 21.8% (95%CI 18.6∓25.6) of cases. In countries that have introduced higher valent PCVs, study periods were largely representative of the transition and early years of PCV10 or PCV13. In these studies, the overall serotype-specific contribution of 19A was lower (14.2% 95%CI 11.1∓18.3). Overall, non-PCV13 serotypes contributed to 42.2% (95%CI 36.1∓49.5%) of childhood IPD cases. However, regional differences were noted (57.8% in North America, 71.9% in Europe, 45.9% in Western Pacific, 28.5% in Latin America, 42.7% in one African country, and 9.2% in one Eastern Mediterranean country). Predominant non-PCV13 serotypes overall were 22F, 12F, 33F, 24F, 15C, 15B, 23B, 10A, and 38 (descending order), but their rank order varied by region.
Conclusion:
Childhood IPD is associated with a wide number of serotypes. In the early years after introduction of higher valent PCVs, non-PCV13 types caused a considerable proportion of childhood IPD. Serotype data, particularly from resource-limited countries with high burden of IPD, are needed to assess the importance of serotypes in different settings. The geographic diversity of pneumococcal serotypes highlights the importance of continued surveillance to guide vaccine design and recommendations.
Related Concept Videos
Pneumonia II: Pathophysiology
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

